Collegium Pharmaceutical (COLL) Income towards Parent Company (2014 - 2026)

Collegium Pharmaceutical's Income towards Parent Company history runs 13 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 499.75% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $74.9 million, a 70.75% increase from a year earlier, with the FY2025 full-year figure at $62.9 million, down 9.13% from the prior year.
• Income towards Parent Company eased to $14.5 million in Q1 2026 per COLL's latest filing, from $17.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $31.9 million in Q4 2023 and bottomed at -$17.4 million in Q1 2023.
• The 5-year median for Income towards Parent Company is $12.5 million (2024), against an average of $10.0 million.
• Across the five-year window, Income towards Parent Company plunged 177.67% in 2022 and soared 4415.1% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$7.2 million in 2022, then soared by 543.67% to $31.9 million in 2023, then sank by 60.75% to $12.5 million in 2024, then surged by 35.31% to $17.0 million in 2025, then declined by 14.54% to $14.5 million in 2026.
• Per Business Quant, the three latest COLL Income towards Parent Company figures stand at $14.5 million (Q1 2026), $17.0 million (Q4 2025), and $31.5 million (Q3 2025).